Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05503797 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion pushed from Jun 27, 2026 to Dec 31, 2027
Study completion pushed from Dec 28, 2026 to Dec 28, 2028
Eligibility criteria expanded, about 8 words
Site details revised at 6 of 70 sites
v28
MinorStudy sites: 69 to 70v27
MinorStudy sites: 67 to 69v26
MinorStudy sites: 66 to 67v25
MinorStudy sites: 64 to 66v24
Show 22 earlier versionsHide 22 earlier versions
MinorSite details revised at 1 of 64 sitesv23
MinorStudy sites: 61 to 64v22
MinorStudy sites: 60 to 61v21
MinorEnrollment target: 250 to 254v20Show 4 more changesShow less
Interventions: Cobicistat (Drug), Plixorafenib (Drug) to Plixorafenib (Drug)
Eligibility criteria shortened, about 36 words
Secondary endpoints: 16 to 13
Site details revised at 6 of 60 sites
MinorStudy sites: 56 to 60v19
MinorStudy sites: 55 to 56v18
NotablePrimary completion date: Jun 27, 2025 to Jun 27, 2026v17Show 4 more changesShow less
Study sites: 53 to 55
Study completion date: Aug 28, 2026 to Dec 28, 2026
Eligibility criteria shortened, about 672 words
Secondary endpoints: 15 to 16
MinorStudy sites: 52 to 53v16
MinorStudy sites: 48 to 52v15
NotableEnrollment target: 135 to 250v14Show 5 more changesShow less
Primary endpoints: 1 to 2
Eligibility criteria expanded, about 522 words
Secondary endpoints revised (15)
Site details revised at 5 of 48 sites
Study arms: 2 to 4
MinorStudy sites: 47 to 48v13
MinorStudy sites: 43 to 47v12
MinorStudy sites: 41 to 43v11
MinorStudy sites: 19 to 41
Interventions: Cobicistat (Drug), FORE8394 (Drug) to Cobicistat (Drug), Plixorafenib (Drug)
Eligibility criteria expanded, about 233 words
Secondary endpoints revised (15)
v10
MinorStudy sites: 16 to 19v9
MinorStudy sites: 13 to 16v8
MinorStudy sites: 10 to 13v7
MinorStudy sites: 3 to 10v6
MinorStart date changed from estimate of Mar 1, 2023 to Feb 21, 2023v5
NotableTrial status: Not Yet Recruiting to Recruiting
Start date: Nov 1, 2022 to Mar 1, 2023
Study sites: 0 to 3
v4
NotableStart date: Oct 1, 2022 to Nov 1, 2022
Primary completion date: Aug 27, 2025 to Jun 27, 2025
Study completion date: Sep 28, 2026 to Aug 28, 2026
v3
NotableStart date: Sep 1, 2022 to Oct 1, 2022v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.